Profusa Signs Term Sheet to Merge with $111M Health Diagnostics Firm
Profusa (PFSA) has signed a non-binding term sheet to merge with a privately held, commercial-stage health diagnostics and toxicology testing company. The combined entity is expected to operate as a national public diagnostics provider featuring CLIA-certified laboratories. The merger aims to create a stronger market presence in the healthcare diagnostics sector by combining Profusa's capabilities with those of an established firm already generating $111 million in revenue. This strategic move could enhance diagnostic services and expand access through publicly traded infrastructure, potentially increasing operational scale and efficiency. While details remain preliminary due to the non-binding nature of the term sheet, market observers may view this as a positive development for Profusa's growth strategy.
Tickers: $PFSA
Topics: CLIA-certified labs health diagnostics toxicology testing